Open access
Open access
Powered by Google Translator Translator

Global & Public Health (all articles)

Covid: Children in UK told to delay jab for 12 weeks after infection.

18 Nov, 2021 | 08:54h | UTC

Covid: Children told to delay jab for 12 weeks after infection – BBC

Original Report: Joint Committee on Vaccination and Immunisation (JCVI) advice on COVID-19 vaccination in people aged 16 to 17 years: 15 November 2021

 

Observational study finds mRNA vaccination is associated with an effectiveness of 85% against Covid-19 hospitalization.

18 Nov, 2021 | 08:49h | UTC

Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity – JAMA

Editorial: Understanding Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination – JAMA

Commentary: COVID-19 vaccines 85% effective against hospital cases but weaken over time – TCTMD

Related Study: Study compares the decline in effectiveness for Moderna, Pfizer, and Janssen vaccines and consequences for mortality.

 

Observational study finds the effectiveness of mRNA vaccination against Covid-19 hospitalization was lower (77%) among immunocompromised adults than among immunocompetent adults (90%).

18 Nov, 2021 | 08:52h | UTC

Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021 – CDC Morbidity and Mortality Weekly Report

Related:

CDC Guidance: Immunocompromised may need a fourth Covid-19 shot.

 

Commentary on Twitter (thread – click for more)

 

8 lingering questions about the new Covid pills from Merck and Pfizer.

18 Nov, 2021 | 08:46h | UTC

8 lingering questions about the new Covid pills from Merck and Pfizer – STAT

Related:

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

Observational study found monitoring outpatients with Covid-19 using text messages that allowed the report of worsening symptoms was associated with improved outcomes.

17 Nov, 2021 | 08:53h | UTC

Comparative Effectiveness of an Automated Text Messaging Service for Monitoring COVID-19 at Home – Annals of Internal Medicine

News Release: Automated Texting System Saved Lives Weekly During First COVID Surge – Penn Medicine

Commentaries:

Monitoring outpatients by text appeared to reduce mortality from COVID-19 – ACP Internist

Texting saved lives during Covid. What does that mean for health care’s future? – STAT

 

Commentary from the author on Twitter (thread – click for more)

 

The big questions about Covid-19 booster shots – “From the why to the who, we still need a lot of answers about booster shots”.

17 Nov, 2021 | 08:48h | UTC

The big questions about Covid-19 booster shots – Vox

 

Commentary on Twitter

 

Pfizer COVID Pill to Be Made, Sold Cheaply in 95 Poor Countries.

17 Nov, 2021 | 08:40h | UTC

Pfizer COVID Pill to Be Made, Sold Cheaply in 95 Poor Countries – HealthDay

See also:

Pfizer agrees to license generic versions of its COVID-19 pill — in some countries – NPR

Pfizer and Medicines Patent Pool Reach ‘Ground-breaking’ Voluntary Licensing Deal for New COVID-19 Treatment Pill – Health Policy Watch

Pfizer Will Allow Its Covid Pill to Be Made and Sold Cheaply in Poor Countries – The New York Times (a few articles per month are free)

 

MSF responds to Pfizer and Medicines Patent Pool license for new Covid-19 treatment – “The deal, however, only covers 53 percent of the world’s population and excludes people in several upper-middle-income countries, leaving this promising medicine out of reach for millions”.

17 Nov, 2021 | 08:38h | UTC

MSF responds to Pfizer and Medicines Patent Pool license for new Covid-19 treatment – Médecins Sans Frontières

 

Commentary on Twitter

 

Long-term follow up of randomized trials found that children who were given nutrient or supplement enriched formula milk as babies didn’t have higher academic performances as adolescents.

17 Nov, 2021 | 08:14h | UTC

News release: Study finds no benefit of enriched formula milks on later academic performance – British Medical Journal

Original Study: Effect of nutritionally modified infant formula on academic performance: linkage of seven dormant randomised controlled trials to national education data – The BMJ

Editorial: Enriched formula milks and academic performance in later childhood – The BMJ

 

Commentary on Twitter

https://twitter.com/bmj_company/status/1458691047933026307

 

Covid: Austria introduces lockdown for unvaccinated.

16 Nov, 2021 | 08:43h | UTC

Covid: Austria introduces lockdown for unvaccinated – BBC

See also: Austria orders nationwide lockdown for the unvaccinated – Associated Press

 

Covid-19: global vaccine production is a mess and shortages are down to more than just hoarding.

16 Nov, 2021 | 08:42h | UTC

Covid-19: global vaccine production is a mess and shortages are down to more than just hoarding – The BMJ

 

Commentary on Twitter

 

Pfizer’s pill is the latest COVID treatment to show promise. Here are some more.

16 Nov, 2021 | 08:41h | UTC

Pfizer’s pill is the latest COVID treatment to show promise. Here are some more – The Conversation

Related:

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

New WHO report maps barriers to insulin availability and suggests actions to promote universal access – “100 years after its discovery, insulin still out of reach for many living with diabetes”.

16 Nov, 2021 | 08:34h | UTC

News Release: New WHO report maps barriers to insulin availability and suggests actions to promote universal access – World Health Organization

Report: Keeping the 100-year-old promise: making insulin access universal – World Health Organization

Commentary: Half the People Living with Diabetes Can’t Afford Insulin, WHO Report Shows – Health Policy Watch

Related:

Editorial | Insulin for all: a hope yet to be realized.

One hundred years of insulin therapy.

The state of diabetes treatment coverage in 55 low-income and middle-income countries – fewer than one in ten people with diabetes in LMICs receive comprehensive care such as low-cost medicines to reduce blood sugar, blood pressure and cholesterol levels, in addition to counseling on diet, exercise and weight.

 

Commentary on Twitter (thread – click for more)

https://twitter.com/WHO/status/1459194472022122500

 

Decarbonising healthcare in low and middle income countries: potential pathways to net zero emissions.

16 Nov, 2021 | 08:15h | UTC

Decarbonising healthcare in low and middle income countries: potential pathways to net zero emissions – The BMJ

 

Commentary on Twitter

 

[Preprint] Risk of severe COVID-19 is rare among fully vaccinated individuals in England.

14 Nov, 2021 | 20:10h | UTC

Commentary: Risk of severe COVID-19 is rare among fully vaccinated individuals in England – News Medical

Original Study: Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: A cohort study from OpenSAFELY – medRxiv

 

Phase 4 RCT: Concomitant administration of COVID-19 vaccines (AstraZeneca or Pfizer) with seasonal influenza vaccines in adults is safe and preserves antibody responses to both vaccines.

14 Nov, 2021 | 20:14h | UTC

Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial – The Lancet

 

Large populational study finds prior SARS-CoV-2 infection reduces the risk of breakthrough infection following mRNA vaccination.

14 Nov, 2021 | 20:12h | UTC

Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar – JAMA

Commentaries:

Vaccine plus previous infection may offer enhanced COVID-19 protection – CIDRAP

Prior SARS-CoV-2 infection and risk of breakthrough infection following mRNA vaccination – News Medical

 

Commentary on Twitter

 

Populational study in Qatar showed the effectiveness against SARS-CoV-2 Delta-induced severe, critical or fatal disease was 93.4% for the Pfizer vaccine and 96.1% for Moderna.

14 Nov, 2021 | 20:11h | UTC

BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar – Nature Medicine

 

Commentary on Twitter

 

What influences people’s responses to public health messages for managing risks and preventing infectious diseases? A rapid systematic review of the evidence and recommendations.

14 Nov, 2021 | 20:06h | UTC

What influences people’s responses to public health messages for managing risks and preventing infectious diseases? A rapid systematic review of the evidence and recommendations – BMJ Open

 

Commentary on Twitter

 

SARS-CoV-2 vaccines are safe and immunogenic in most people with cancer, according to study.

14 Nov, 2021 | 20:05h | UTC

News Release: SARS-CoV-2 vaccines are safe and immunogenic in most people with cancer, according to study – Harvard Medical School

Original study: Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study – Journal of Clinical Oncology

 

Commentary from the author on Twitter (thread – click for more)

 

#AHA21 – RCT: Among children and adolescents who had screening echocardiograms and were identified as having latent rheumatic heart disease, secondary antibiotic prophylaxis with penicillin G benzathine for 2 years was associated with reduced echocardiographic progression (0.8 vs. 8.2% in the control group).

14 Nov, 2021 | 20:03h | UTC

Secondary Antibiotic Prophylaxis for Latent Rheumatic Heart Disease – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries:

Penicillin significantly reduces rheumatic heart disease progression in children – Murdoch Children’s Research Institute

Penicillin slows devastating impacts of rheumatic heart disease in children from Uganda – Children’s National Hospital

Secondary Antibiotic Prophylaxis for Latent Rheumatic Heart Disease – American College of Cardiology

 

Commentaries on Twitter

 

Editorial: COVID is disrupting scientific careers around the world.

14 Nov, 2021 | 20:08h | UTC

COVID is disrupting scientific careers around the world – Nature

See also:

Scientists count the career costs of COVID – Nature

Potentially long-lasting effects of the pandemic on scientists – Nature

 

Global, regional, and national mortality among young people aged 10–24 years, 1950–2019: a systematic analysis for the Global Burden of Disease Study 2019.

14 Nov, 2021 | 19:45h | UTC

Global, regional, and national mortality among young people aged 10–24 years, 1950–2019: a systematic analysis for the Global Burden of Disease Study 2019 – The Lancet

Commentary: Nearly two-thirds of those who died young in 2019 were male, research finds – The Guardian

 

Commentary on Twitter (thread – click for more)

 

RCT: BBV152 (India’s COVAXIN) has an overall vaccine efficacy of 77.8% against symptomatic Covid-19 in adults.

12 Nov, 2021 | 10:43h | UTC

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial – The Lancet

Invited Commentary: Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19 – The Lancet

Related: WHO issues emergency use approval for India’s Covaxin.

 

Commentary on Twitter

 

Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year – “In total, 99.995% of children and young people with a positive SARS-CoV-2 test survived”.

12 Nov, 2021 | 10:39h | UTC

Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year – Nature

Related:

[Preprint] Study confirms children’s extremely low risk of death from Covid-19 – “99·995% of children and young people with a positive SARS-CoV-2 test survived”.

Study: Children and young people remain at low risk of COVID-19 mortality

 

Commentaries on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.